Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Glaxo SmithKline EU Merger Approval Includes Potential Divestment Of Ariflo

  • News

Executive Summary

Glaxo SmithKline will be required to divest the chronic obstructive pulmonary disease therapy Ariflo in Europe if all competing agents fail in clinical trials.

You may also be interested in...



SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate

SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.

SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate

SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.

FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB

The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.

Table

View full table

Tags:
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS036030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By